{"prompt": "['Amended Clinical Trial Protocol No. 05', '15-Dec-2021', 'GZ402673-EFC13429 - alemtuzumab', 'Version number: 1', 'ACUTE RENAL FAILURE', 'Rapid increase in serum creatinine over 150 mol/L', 'or rapid decrease in creatinine clearance below', '50 mL/mn', 'Can be rapidly reversed:', 'Cannot be rapidly reversed:', 'By volume repletion', 'Occurrence/aggravation of life', 'Or relief of urinary tract', 'threatening symptoms of ARF: anemia,', 'obstruction (according to etiology)', 'hyperkalemia, hyperuricemia, metabolic', 'acidosis, cardiac insufficiency,', 'pulmonary edema, arrhythmia, DIC, etc.', 'And/or predominant elimination of', 'Investigational Medicinal Product by', 'renal route', '1.', 'INFORM the local monitor', '2.', 'DISCONTINUE', '1.', 'Investigational Medicinal', 'Investigational Medicinal Product', 'Product may be continued', 'administration', '2.', 'MONITOR serum creatinine', '3.', 'HOSPITALIZATION should be', 'until return to baseline level', 'considered and seek for nephrologic', 'advice', '4.', 'PERFORM the following', 'examinations:', 'BP, HR, hydration status, ECG', 'Blood count', 'Liver function tests + CPK', 'Biochemistry, including urea', 'Urinalysis', '5.', 'COLLECT/STORE one sample', 'following handling procedures', 'described in PK sections (for studies', 'with PK sampling) and freeze one', 'serum sample (5 mL) on Day 1', '(cessation of investigational', 'medicinal product)', '6.', 'MONITOR renal function until', 'return to baseline level (every day at', 'the beginning, then every week)', 'Acute renal failure is to be recorded as an AE only if at least 1 of the criteria listed in the general', 'guidelines for reporting AEs in Section 10.4.5 is met.', 'Property of the Sanofi Group - strictly confidential', 'Page 111', 'VV-CLIN-02544065 5.0']['Amended Clinical Trial Protocol No. 05', '15-Dec-2021', 'GZ402673-EFC13429 - alemtuzumab', 'Version number: 1', 'SUSPICION OF RHABDOMYOLYSIS', 'Muscular symptoms (myalgia, pain, weakness,', 'Systematic CPK assessment as per', 'dark urines)', 'protocol', 'Perform CPK', 'If Increase in CPK (expressed in ULN)', '> 3 ULN', 'Repeat immediately the count.', 'If confirmed, inform the local monitor and', 'INVESTIGATE for the origin:', '- PERFORM:', 'ECG', 'CPK-MB -MM', 'Troponin', 'Creatinine', 'Iono (k+, Ca2+)', 'Transaminases + Total and conjugated bilirubin', 'Myoglobin (serum and urines)', '- COLLECT/STORE one sample following handling procedures described in PK sections (for', 'studies with PK sampling) and freeze one serum sample (5 mL) on Day 1 (cessation of', 'investigational medicinal product).', '- INTERVIEW the patient about a recent intensive muscular effort, trauma, convulsions, electrical', 'injury, injury or stress to the skeletal muscle, multiple intramuscular injections, recent surgery,', 'concomitant medications, consumption of alcohol, morphine, cocaine.', '-', 'SEARCH for alternative causes to cardiac or muscular toxicity, ie: stroke, pulmonary infarction,', 'dermatomyositis or polymyositis, convulsions, hypothyroidism, delirium tremens, muscular', 'dystrophies.', 'If the cardiac origin or the rhabdomyolysis is', 'If either the cardiac origin or the', 'ruled out and if CPK 10 ULN:', 'rhabdomyolysis is confirmed or if CPK', 'MONITOR CPK every 3 days for the first week', '> 10 ULN:', 'then once weekly until return to normal or for', '1. DISCONTINUE Investigational', 'at least 3 months', 'Medicinal Product administration', '2. MONITOR CPK every 3 days for the', 'first week then once weekly until return', 'to normal or for at least 3 months', '3. HOSPITALIZATION should be', 'considered', 'Suspicion of rhabdomyolysis is to be recorded as an AE only if at least 1 of the criteria in the', 'general guidelines for reporting AEs in Section 10.4.5 is met.', 'Property of the Sanofi Group - strictly confidential', 'Page 112', 'VV-CLIN-02544065.0']\n\n###\n\n", "completion": "END"}